araag2/HINT huggingface dataset:
Clinical trial NCT00202800 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, etoposide
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locally advanced or metastatic adenocarcinoma of the pancreas.

          -  Patients may have received prior immunotherapy, radiation therapy, or surgery, but
             must be > 4 weeks out from therapy and have recovered fully from its effects.

          -  Patients must be 18 years of age or older.

          -  Patients must have unidimensional measurements obtainable using RECIST criteria (see
             Protocol Attachment E).

          -  Karnofsky Performance Scale must be 50 or better (see Protocol Attachment A).

          -  Patient must have the following hematologic and chemical parameters:

               -  ANC > 1,000 cells/mm3

               -  Hemoglobin > 9 gm/dL

               -  Platelets > 100,000 cells/mm3

               -  SGOT/SGPT < 3 x normal, unless there is known liver involvement. Then they must
                  be < 5x normal.

               -  Bilirubin < 2.0 mg/dL

               -  Creatinine < 2.0 mg/dL

          -  Female within childbearing years must use an accepted contraceptive method.

          -  Patient must have a life expectancy of at least eight (8) weeks.

          -  A signed informed consent must be obtained prior to study entry.

        Exclusion Criteria:

          -  Previous chemotherapy with the exception of 5FU given as part of an adjuvant regimen.

          -  Pregnant or nursing females.

          -  Concurrent radiation therapy.

          -  Patients with other active neoplasms are ineligible.

          -  Patients with serious active infections or other underlying medical conditions, which
             would impair their ability to receive the treatment as prescribed.

        Disease Diagnostic Criteria and Staging:

          -  Patients must have a histologic or cytologic diagnosis of locally advanced or
             metastatic adenocarcinoma of the pancreas using standard pathologic criteria.

          -  Staging will be according to AJCC criteria.
Clinical trial NCT00058487 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: epirubicin hydrochloride, thalidomide
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatocellular carcinoma

               -  Locally unresectable or metastatic disease

          -  Measurable disease

          -  No clinically apparent CNS metastases

          -  No carcinomatous meningitis

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 75,000/mm^3

        Hepatic

          -  SGOT no greater than 5 times upper limit of normal

          -  Bilirubin no greater than 3.0 mg/dL

          -  INR no greater than 1.5*

          -  Albumin at least 2.0 g/dL NOTE: *Not required for patients receiving full
             anticoagulation with warfarin for deep vein thrombosis or pulmonary embolism

        Renal

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  LVEF normal by echocardiogram or MUGA

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Willing and able to participate in the System for Thalidomide Education and
             Prescribing Safety (STEPS) program

          -  No uncontrolled serious medical or psychiatric illness

          -  No other concurrent uncontrolled malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No more than 1 prior chemotherapy regimen for hepatocellular carcinoma

          -  No prior chemoembolization to the liver

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  More than 2 weeks since prior major surgery
Clinical trial NCT00129441 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: merck l-830982, placebo
SMILES: CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male participants

          -  Between the ages of 18 and 50

          -  Meet diagnostic criteria for schizophrenia or schizoaffective disorder

          -  Are clinically stable for a minimum of 3 months on current dose of medication

          -  Are unemployed (i.e., work less than 20 hours per week at competitive employment)

        Exclusion Criteria:

          -  Psychoactive substance dependence within the past 6 months or substance abuse within
             the past month

          -  History of head trauma or other neurological disorder

          -  Medical illness or medications, such as benzodiazepine treatment or HIV medications,
             that may be affected by study participation (the study doctor will discuss this with
             potential subjects)

          -  Mental retardation

          -  Seizure disorder

          -  History of a heart attack, arrhythmia, or other heart disease
Clinical trial NCT00490880 (phase 2, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven urothelial carcinoma of the urinary bladder in
             stage T2b-T3, N0/Nx, M0.

          -  Patients must have measurable disease. Response assessment will be evaluated according
             to RECIST criteria. Measurable lesions with clearly defined margins will be evaluated
             by X-Ray, Transvesical Ultrasound, CT-Scan or MRI, cystoscopy.

          -  Lesions serving as measurable disease must have the longest diameter of greater than
             or equal to 20 mm as measured with conventional techniques or greater than or equal 10
             mm with spiral CT scan. Lesions measured by physical examination must have a longest
             diameter of greater than or equal 20 mm.

        Exclusion Criteria:

          -  Patients with prior or concomitant malignant diseases (other than appropriately
             treated basal cell carcinoma of the skin or carcinoma of the cervix)

          -  PSA greater than 5.0 ng/mL

          -  Concurrent administration of any other tumor therapy, including radiotherapy,
             cytotoxic chemotherapy, immunotherapy, molecular target therapy.
Clinical trial NCT00183989 (phase 2, status: terminated)
Conditions: mantle cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: fludarabine, mitoxantrone and rituximab
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell sub-type lymphoma
             only, as determined by morphologic assessment and consistent immunophemotypic markers

          -  Newly diagnosed and patients who have received prior treatment are eligible

          -  Measurable or evaluable disease

          -  Karnofsky performance status greater or equal to 50%

          -  Men and women, age greater or equal to 18 years old

          -  AGC greater or equal to 1.0; platelets greater or equal to 75,000; Hemoglobin greater
             or equal to 8.0 (unless because of lymphomatous infiltration of the marrow)

          -  Creatinine less than 2.0; bilirubin less than 2.0; SGOT less than 3 times upper limit
             of normal (unless elevations are due to lymphomatous involvement)

          -  Women of child bearing potential must have negative pregnancy test within 14 days of
             study entry.

          -  Signed informed consent

        Exclusion Criteria:

          -  History of congestive heart failure or significant cardiac disease

          -  Prior exposure to either fludarabine or mitoxantrone. Prior exposure to rituximab
             allowed

          -  Active infection

          -  HIV seropositive

          -  Pregnant or lactating females

          -  Second active malignancy, other than squamous cell skin cancer,in-situ cervical
             cancer, or history of other cancer diagnosed within the preceding 5 years

          -  Presence of psychological or emotional disorders which would make valid informed
             consent impossible
Clinical trial NCT00049348 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: cisplatin, fluorouracil, gemcitabine hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the pancreas

               -  No adenosquamous cancers or adenocarcinoma associated with cystic mucinous
                  neoplasms

               -  Locally advanced disease that is potentially resectable, previously explored and
                  considered unresectable, or deemed to require preoperative treatment for other
                  reasons

               -  Primary cancer in the head, body, or tail of pancreas

          -  Measurable disease

          -  No 360 degree encirclement of the superior mesenteric artery, hepatic artery, or
             celiac axis

          -  No metastases by CT scan and laparoscopy (if prior surgery, only CT scan required)

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute granulocyte count greater than 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic

          -  Bilirubin less than 2 mg/dL (unless secondary to bile duct blockage by tumor)

          -  Biliary obstruction by tumor requires biliary stent at least 9 French or biliary
             bypass before therapy

        Renal

          -  Creatinine less than 1.7 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Other

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for this disease

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy to pancreas

        Surgery

          -  Not specified
Clinical trial NCT01668641 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: glpg0634, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have active RA as shown by five or more swollen joints (from the 66-joint count), five
             or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;

          -  Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25
             mg/week for at least 4 weeks prior to screening and willing to continue on this
             regimen for the duration of the study;

          -  If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or
             prednisone equivalent and stable for at least 4 weeks prior to screening;

          -  If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable
             dose for at least 2 weeks prior to screening;

          -  Female subjects must have a negative pregnancy test unless they are surgically sterile
             or have been post-menopausal for at least one year;

          -  Women of childbearing potential must use a medically acceptable means of birth control
             and agree to continue its use during the study and for at least 12 weeks after the
             last dose of study drug.

          -  Sexually active men must agree to use a medically acceptable form of contraception
             during the study and continue its use for at least 3 months after the last dose of
             study drug; and

          -  Able and willing to sign the informed consent prior to screening evaluations and agree
             to schedule of assessments.

        Exclusion Criteria:

          -  Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background
             methotrexate;

          -  Current or previous RA treatment with a biological agent, with the exception of
             biologics administered in a clinical study setting more than six months prior to
             screening (12 months for rituximab or other B cell depleting agents);

          -  Previous treatment at any time with a cytotoxic agent, other than methotrexate, before
             screening;

          -  Previous use of the study drug GLPG0634;

          -  Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks
             prior to screening;

          -  Known hypersensitivity to study drug ingredients or a significant allergic reaction to
             any drug as determined by the Investigator;

          -  Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from
             any cause with the exception of hepatitis A;

          -  History of any inflammatory rheumatological disorders other than RA;

          -  History of tuberculosis (TB) infection
Clinical trial NCT00039130 (phase 2, status: completed)
Conditions: leukemia, lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, allopurinol
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically, cytogenetically, or immunophenotypically confirmed Burkitt's leukemia
             or Burkitt's or Burkitt-like lymphoma

               -  L3 morphology surface IgG expression

               -  Cytogenetic evidence for t(8;14), t(8;22), or t(2;8)

          -  Previously untreated disease except hydroxyurea for leukocytosis

          -  CNS involvement allowed

          -  Patients with Burkitt's leukemia or Burkitt's lymphoma with bone marrow involvement
             must also be enrolled on CALGB-8461

          -  Patients with Burkitt's leukemia must also be enrolled on CALGB-9665

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and over

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Other:

          -  HIV negative

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent interleukin-11

        Chemotherapy:

          -  See Disease Characteristics

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal therapy except for non-disease-related conditions (e.g.,
             insulin for diabetes)

          -  No concurrent steroids except for adrenal failure

        Radiotherapy:

          -  No concurrent palliative radiotherapy except whole-brain irradiation for documented
             CNS disease
Clinical trial NCT00114309 (phase 2, status: unknown status)
Conditions: malignant glioma, glioblastoma multiforme, gbm, anaplastic astrocytoma, oligo-astrocytoma, gliosarcoma
ICD codes: R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0, L51.0, L51.8, L51.9, C84.67, C84.77, C84.7A, C84.60, C84.70, C84.62, C84.66
Drugs: 131-i-tm-601, 131i-tm601
SMILES: CCC(C(C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have a histologically confirmed unilateral, supratentorial malignant
             glioma (grade 3 or 4, anaplastic astrocytoma, gliosarcoma, glioblastoma multiforme or
             malignant oligoastrocytoma)

          -  Patient must have glioma progression or recurrence following radiotherapy that was no
             less than 50 Gy (+/- chemotherapy; +/- surgery)

          -  Patient must be a candidate for resection of the recurrent tumor (surgical
             requirements are detailed in the study protocol)

          -  Imaging must show recurrent, unilateral, supratentorial tumor(s)

          -  There is no diffuse leptomeningeal disease

          -  For patients with previous radiosurgery or enhanced radiotherapy, based on
             neurosurgeon's judgment, the area of enhancement can be removed during the surgery

          -  Patient must have recovered from toxicity of prior therapy

          -  Patient must be > 18 years of age.

          -  Patient has a Karnofsky Performance Status greater than or equal to 60%

          -  Patient must have a life expectancy of at least 3 months

          -  Patient has no uncontrolled seizures or other neurological conditions which would
             interfere with evaluation

          -  Patient is not currently receiving, or is not anticipated to receive, concomitant
             anticancer agent(s) during the course of this study

          -  Patient must have given informed consent

        Exclusion Criteria:

          -  Patient with concurrent malignancy (except curatively treated basal or squamous cell
             carcinoma of the skin or carcinoma in situ of cervix and/or breast) or patients with
             prior malignancies that have not been disease-free for five years

          -  Patient has presence of non-contiguous satellite lesions

          -  Patient with known allergy to iodine, iodine containing drugs or contrast agent

          -  Patient with the potential for pregnancy or impregnating their partner and who do not
             agree to follow an acceptable birth control method to avoid conception

          -  Pregnant or breast feeding females

          -  Patient is not maintained on a stable corticosteroid regimen

          -  New onset of conditions not present prior to surgery (as detailed in Study Protocol)
             which would make patient an inappropriate study candidate, or as determined by
             Investigator
Clinical trial NCT00455507 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: istradefylline, istradefylline, placebo
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. UK Parkinson's Disease Society (UKPDS) brain bank criteria (Step 1 and 2) for PD.

          2. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale.

          3. On levodopa/dopa-decarboxylase inhibitor for at least one year.

          4. Taking at least three doses and >=300mg of levodopa per day for at least four weeks
             before randomization.

          5. Predictable end of dose wearing off.

          6. Able to satisfactorily complete Hauser based 24-hour patient Parkinson's diary.

          7. Have an average of two hours of OFF time on 24-hour diaries.

          8. On a stable regimen of any other anti-Parkinson's drugs for at least four weeks before
             randomization.

          9. Be at least 20 years of age.

         10. Be willing and able to give written informed consent.

        Exclusion Criteria:

          1. Taking any excluded medications.

          2. Neurosurgical treatment or Transcranial Magnetic Stimulation for PD.

          3. Diagnosis of cancer within 5 years.

          4. Diagnosis of clinically significant illness of any organ system.

          5. Diagnosis of dementia or mini-mental status examination score of 25 or less.

          6. History of drug or alcohol abuse or dependence within the past two years.

          7. History of psychosis.

          8. Significant drug allergies.

          9. Taking anticonvulsants for seizures.

         10. History of neurological malignant syndrome.

         11. Pregnant or lactating females.
Clinical trial NCT00559754 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bevacizumab [avastin], docetaxel, standard chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [Ta]
Eligibility criteria:

        Inclusion Criteria:

          -  female patients, >=18 years of age;

          -  primary HER2-negative operable breast cancer;

          -  tumor >2cm in size;

          -  ECOG performance status 0-1.

        Exclusion Criteria:

          -  previous treatment for breast cancer;

          -  metastatic disease;

          -  current or recent (within 10 days of first dose of Avastin) use of aspirin
             (>325mg/day) or full-dose anticoagulants for therapeutic purposes;

          -  clinically significant cardiovascular disease.